Zobrazeno 1 - 10
of 86
pro vyhledávání: '"John P O'Bryan"'
Autor:
Kalyani Sonawane, Ketki N. Borse, Melanie Jefferson, Haluk Damgacioglu, Matthew J. Carpenter, John L. Pearce, Besim Ogretmen, Sophie Paczesny, John P. O’Bryan, Jihad S. Obeid, Marvella E. Ford, Ashish A. Deshmukh
Publikováno v:
Preventive Oncology & Epidemiology, Vol 2, Iss 1 (2024)
Background: Communicating complex and diverse catchment area data effectively can transform cancer prevention and care delivery and strengthen community engagement efforts of cancer centersObjective: Describe a systematic, stakeholder-driven, and the
Externí odkaz:
https://doaj.org/article/b5b2687bac3441c6b65725d34f9a8369
Autor:
Laila Elsherif, Xuerong Wang, Milana Grachoff, Beata M Wolska, David L Geenen, John P O'Bryan
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30129 (2012)
Mice expressing the tetracycline transactivator (tTA) transcription factor driven by the rat α-myosin heavy chain promoter (α-MHC-tTA) are widely used to dissect the molecular mechanisms involved in cardiac development and disease. However, these
Externí odkaz:
https://doaj.org/article/f2e0bab7c5f441909bee50af9cdfa3d1
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e45360 (2012)
The intersectin 1 (ITSN1) scaffold stimulates Ras activation on endocytic vesicles without activating classic Ras effectors. The identification of Class II phosphatidylinositol 3-kinase beta, PI3KC2β, as an ITSN1 target on vesicles and the presence
Externí odkaz:
https://doaj.org/article/31ac0d3c9cf54ce1aceb4a53623d1ee1
Autor:
Katy A Wong, Jessica Wilson, Angela Russo, Li Wang, Mustafa Nazir Okur, Xuerong Wang, Negin P Martin, Erica Scappini, Graeme K Carnegie, John P O'Bryan
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e36023 (2012)
Members of the intersectin (ITSN) family of scaffold proteins consist of multiple modular domains, each with distinct ligand preferences. Although ITSNs were initially implicated in the regulation of endocytosis, subsequent studies have revealed a mo
Externí odkaz:
https://doaj.org/article/83cd7a04befd4801a3e800de61643c21
Autor:
Dipankar Ash, Varadarajan Sudhahar, Seock-Won Youn, Mustafa Nazir Okur, Archita Das, John P. O’Bryan, Maggie McMenamin, Yali Hou, Jack H. Kaplan, Tohru Fukai, Masuko Ushio-Fukai
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
The role of endothelial copper transporter ATP7A in vascular function and angiogenesis remains largely unexplored. Here the authors show that ATP7A promotes VEGFR2 signaling and angiogenesis by limiting autophagy-mediated degradation of VEGFR2, which
Externí odkaz:
https://doaj.org/article/7349411310e2453bb951aceb39ac7122
Autor:
Kai Wen Teng, Steven T. Tsai, Takamitsu Hattori, Carmine Fedele, Akiko Koide, Chao Yang, Xuben Hou, Yingkai Zhang, Benjamin G. Neel, John P. O’Bryan, Shohei Koide
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Most oncogenic RAS mutants remain undruggable. Here, the authors developed monobodies that selectively recognize the active state of KRAS(G12V) and KRAS(G12C) and demonstrated their utility in inhibiting RAS functions through inhibition and degradati
Externí odkaz:
https://doaj.org/article/1c4337f6a3694e9b96918c1bb0fcb1f7
Autor:
Imran Khan, Akiko Koide, Mariyam Zuberi, Gayatri Ketavarapu, Eric Denbaum, Kai Wen Teng, J. Matthew Rhett, Russell Spencer-Smith, G. Aaron Hobbs, Ernest Ramsay Camp, Shohei Koide, John P. O'Bryan
Publikováno v:
Cell Reports, Vol 38, Iss 6, Pp 110322- (2022)
Summary: RAS guanosine triphosphatases (GTPases) are mutated in nearly 20% of human tumors, making them an attractive therapeutic target. Following our discovery that nucleotide-free RAS (apo RAS) regulates cell signaling, we selectively target this
Externí odkaz:
https://doaj.org/article/c9a4430bc9ea408bb3a1d81302e52240
Autor:
Michael C. Ostrowski, Catherine MarElia-Bennet, Cynthia J. Timmers, Akiko Koide, John P. O'Bryan, Mariyam Zuberi, Julia E. Lefler, Thierry Pécot, Eric Denbaum, Dean M. Connor, Imran Khan, Ann-Marie Broome, Shohei Koide
Publikováno v:
Small GTPases
RAS is the most frequently mutated oncogene in human cancer with nearly ~20% of cancer patients possessing mutations in one of three RAS genes (K, N or HRAS). However, KRAS is mutated in nearly 90% of pancreatic ductal carcinomas (PDAC). Although pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22b6e246d4dd430d97346f7a1be535e1
https://doi.org/10.1080/21541248.2021.1906621
https://doi.org/10.1080/21541248.2021.1906621
Autor:
Takamitsu Hattori, Padma Akkapeddi, Imran Khan, Akiko Koide, Eliezra Glasser, Gayatri Ketavarapu, Michael Whaby, Mariyam Zuberi, Kai Wen Teng, Julia Lefler, Lorenzo Maso, Injin Bang, Michael C. Ostrowski, John P. O’Bryan, Shohei Koide
Publikováno v:
Molecular Cancer Research. 21:B013-B013
The G12D mutation is among the most common KRAS mutations associated with cancer, in particular pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are highly selective to KRAS(G12D) over KRAS(wild type) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::057cdf46cb1c25a1f62cee891acca1fe
https://doi.org/10.1158/1557-3125.ras23-b013
https://doi.org/10.1158/1557-3125.ras23-b013
Abstract B023: Inhibition of RAS signaling and tumorigenesis through targeting novel vulnerabilities
Autor:
Imran Kahn, Akiko Koide, Mariyam Zuberi, Gayatri Ketavarapu, Eric Denbaum, Kai Wen Teng, J. Matthew Rhett, Russell Spencer-Smith, G. Aaron Hobbs, Earnest Ramsay Camp, Shohei Koide, John P. O'Bryan
Publikováno v:
Molecular Cancer Research. 21:B023-B023
RAS GTPases are important mediators of oncogenesis with nearly 30% of human tumors harboring mutant RAS proteins. However, pharmacological inhibition of RAS has proven challenging. We have employed Monobody technology to discover novel vulnerabilitie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e59dc84a8514a1c5bd262386625793a9
https://doi.org/10.1158/1557-3125.ras23-b023
https://doi.org/10.1158/1557-3125.ras23-b023